Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NTEC

Intec Pharma (NTEC) Stock Price, News & Analysis

Intec Pharma logo

About Intec Pharma Stock (NASDAQ:NTEC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$9.15
$36.20
52-Week Range
N/A
Volume
988,300 shs
Average Volume
543,436 shs
Market Capitalization
$8.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NTEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

NTEC Stock News Headlines

Indaptus Therapeutics reports Q3 EPS (32c) vs. (47c) last year
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
X4 Pharmaceuticals, Inc. (XFOR)
INDP Indaptus Therapeutics, Inc.
See More Headlines

NTEC Stock Analysis - Frequently Asked Questions

Intec Pharma Ltd (NASDAQ:NTEC) released its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.48) by $0.36.

Intec Pharma shares reverse split on the morning of Tuesday, July 27th 2021.The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Intec Pharma (NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intec Pharma investors own include FuelCell Energy (FCEL), NVIDIA (NVDA), Ovid Therapeutics (OVID), Plug Power (PLUG), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and Lipocine (LPCN).

Company Calendar

Last Earnings
5/17/2021
Today
7/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NTEC
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.13 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$16.18 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8.65 million
Optionable
Optionable
Beta
0.83
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:NTEC) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners